Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

A Breakthrough Therapeutic “Cold Laser” Device for Healthcare Professionals & Mature and/or Active Lifestyle Adults


#lumacare #lumacareduo #coldlasers #CES #Utah #siliconslopes #lowlevellasertherapy

LumaCare’s new LumaCare Duo is a lightweight, handheld, wireless and rechargeable “Cold Laser” system that helps reduce/eliminate pain, and treat minor, traumatic and chronic injuries

The 2 ‘Cold Laser’ emitter heads of the LumaCare Duo allow users to treat an injury from two directions simultaneously with this Low-Level Laser Therapy system.

LumaCare™ today announced that it has begun shipping its first product: The LumaCare Duo™.

The LumaCare Duo is a handheld, wireless, and rechargeable “Cold Laser” device that features two rotating emitter heads, one each at opposite ends of jointed arms, treatment heads that offer nearly 180 degrees of motion for delivering three different pulsing spectrums of therapeutic light to injured body parts. Each emitter head has a peak combined power output of 60 Watts from the 15 laser diodes and LEDs, specifically:

  •     Four Infrared laser diodes at 905nm (nanometer wavelengths),
  •     Six Infrared laser diodes at 808nm, and
  •     Five visible Red LEDs at 670nm,


for a total of 30 laser diodes/LEDs per LumaCare Duo system.

Because the patent-pending LumaCare Duo features two articulating emitter heads affixed to the ends of two movable arms, users can manipulate the device to direct therapeutic laser light at injured tissue from two directions at the same time. Additionally, having two separate and movable treatment heads also allows LumaCare Duo users to focus more Infrared and visible Red light over a wider area if needed. Users may also choose to implement only one emitter head if that is what the treatment protocol requires.

“The Cold Laser market has seen steady growth for over five decades, but very little true innovation,” said Kevin Waller, COO and co-founder of LumaCare. “So we decided to shake things up and launch a powerful, lightweight, wireless Low-Level Laser Therapy system that can be deployed virtually anywhere, while also giving users the ability the option to deliver healing and pain-reducing Cold Laser light from two emitter heads simultaneously.

“When we first unveiled the LumaCare Duo this January at the CES International trade show, we met with a fair amount of healthcare professionals and consumers who knew about (or were users of) Cold Lasers while we were in Vegas. And the fact that the LumaCare Duo emitter heads could rotate to direct Red and Infrared light from two directions simultaneously at the same pain point was simply mind-blowing to them. Hence, we believe that a lot of healthcare professionals will similarly ‘go crazy’ once they learn about this unique approach to Low-Level Laser Therapy treatments.”

BACKGROUND ON LUMACARE, COLD LASERS, AND LUMACARE DUO DETAILS

The LumaCare Duo was born inside National Laser Company, a Salt Lake City-based industrial, commercial and medical laser company for the past 33 years, a firm that has primarily worked behind the scenes as a private label and/or original equipment manufacturer (OEM) and service provider to other laser companies.

With this 30-plus years of laser industry experience as a foundation, the team at LumaCare was quite familiar with the role of Cold Lasers / LLLT as a treatment protocol for a wide variety of chronic and traumatic injuries. So its team decided to put its industry-leading laser expertise to work at crafting an entirely new paradigm in Cold Laser systems; hence, the birth of the LumaCare Duo.

The very first inkling of the potential therapeutic benefits of LLLT came in 1967 when Endre Mester discovered that treatments of Cold Laser light regrew hair on mice. Studies in the ensuing 50-plus years have shown particular benefit from three wavelength bandwidths: from 650—675nm for surface/skin-level treatments, from 800—825nm for medium depth treatments, and from 900—925nm for deeper tissue/joint treatments.

Since Dr. Mester’s finding, hundreds of thousands of Cold Laser systems have been used worldwide to improve blood flow, boost oxygenation, reduce inflammation and pain, and enhance cellular recovery for traumatic and chronic injuries.

The LumaCare Duo weighs 10.75 ounces, measures 4.75- x 5.63- x 2.75-inches (height x width x depth) when folded/closed and 3.25- x 11.50- x 2.75-in. when fully open, while the emitter heads measure 2.1- x 2.7- x 0.6-in. The range of motion of the LumaCare Duo is ~85 degrees per arm and ~130 degrees per emitter head, with a total range of motion of ~180 degrees when the device is fully open.

The LumaCare Duo draws 100-240V 50/60Hz at 0.4A while charging, with an output of 18VDC at 450mA. Continuous treatment time with the LumaCare Duo is over five (5) hours per charge.

The LumaCare Duo is registered with the U.S. Food and Drug Administration as a Class 1 laser and has a suggested retail price of $2,500.00 (US). To purchase or learn more about the LumaCare Duo, please visit https://www.lumacarelasers.com/product/lumacare-duo/.

Or for more information about LumaCare, please call 385-549-1104 or email info@LumaCareLasers.com.

Relevant Hashtags: #LumaCare, #LumaCareDuo, #medtech, #healthtech, #ColdLasers, #LLLT, #CoolLaser, #laser, #lasertech, #healthcare, #medical, #medicine, #treatment #LowLevelLaserTherapy

LumaCare, LumaCare Duo and the LumaCare and LumaCare Duo logos are trademarks of National Laser Company. Any other trademarks are property of their respective owners.

# # #

CONTACT:

David Politis, LumaCare’s VP of Marketing & Sales, 385-549-1104 (work), 801-556-8184 (cell), dpolitis@LumaCareLasers.com

Share article on social media or email:

A Trio of Vendors Earn PaceSetter Awards from Keypoint Intelligence for Their Healthcare Expertise in North America


News Image

The leading manufacturers of office document technology have stepped up their role in supporting their healthcare customers with time- and money-saving solutions for better workflows.

Keypoint Intelligence, the world’s leading independent evaluator of document imaging hardware, software, and services, today announced the recipients of its Buyers Lab (BLI) PaceSetter awards in Healthcare. Based on research conducted in the North American market, these accolades recognize document imaging OEMs that have proven that they offer the hardware and software portfolios, professional services, support, and thought leadership to best serve healthcare customers.

The winners for 2021–2022 are:

CANON U.S.A., INC.

BLI PaceSetter 2021–2022 in Healthcare: Visionary Leader

HP INC.

BLI PaceSetter 2021–2022 in Healthcare: Visionary Leader

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A., INC.

BLI PaceSetter 2021–2022 in Healthcare: Visionary Leader

“There is nothing like a global health emergency to drive home the importance of the healthcare sector,” said Jamie Bsales, Keypoint Intelligence’s Director of Smart Workplace & Security Analysis. “The leading manufacturers of office document technology have stepped up their role in supporting their healthcare customers with time- and money-saving solutions for better workflows. The visionary vendors have expanded beyond the document imaging space to also deliver innovative medical technology to advance healthcare research and improve patient outcomes.”

To determine which companies lead the market, Keypoint Intelligence conducted an in-depth evaluation of the healthcare-related offerings of most of the major document imaging OEMs. The granular study drilled into over 50 points of differentiation spread across key categories: market vision and leadership, MFP/printer hardware and security, software, service/support, professional services, and relevant product offerings beyond document imaging. The analysis included a proprietary scoring rubric to codify a vendor’s strengths, and those that receive top scores are named as PaceSetters for the industry.

Canon shined in the areas of print technology and solutions, bolstered by its expansive ecosystem of offerings that work together to enable healthcare workers to be productive and focus on patient care. Canon’s service capabilities are also a strong suit. “From compact-yet-feature-rich imageCLASS MFPs and printers to reliable imageFORMULA scanners to robust imageRUNNER ADVANCE MFPs, all enhanced with top-notch solutions and service, Canon has the full range of document imaging technology any healthcare provider could require,” said Bsales. “And Canon pushes beyond document imaging with technology for patient diagnosis and treatment such as digital radiography solutions, ultrasound products, retinal cameras, and genotyping technology.”

In addition to award-winning security, HP’s MFP and printer technology incorporates other on-trend capabilities in healthcare. For instance, the HP Workpath Platform supports the development of healthcare-specific workflow tools, while a new Healthcare Edition MFP responds to cleanliness requirements, featuring keyboards, control panels and covers that can be disinfected. The HP Healthcare Advisory Council allows the company to gain insights into what clinicians need to attain that goal. “The focus for HP’s healthcare business has been on helping the company’s customers improve patient outcomes through innovative technologies,” Bsales noted. “The company’s expansion into new areas, like microfluidics, gives promise for treating and eradicating disease.”

“Konica Minolta goes well beyond document imaging devices and software to provide in-demand solutions for hospitals and group practices across the country,” said Bsales. “Its All Covered IT services division aids with HIPAA/HITECH compliance, electronic health records systems implementation and support, healthcare application development, and more, while its Return to Work program is designed to help curb the spread of COVID-19 as employees get back to the office.” The unique Return to Work offering combines a range of the company’s technologies that together provide a comprehensive step-by-step program to help customers re-open offices safely. The company’s IT services for healthcare include HIPAA-compliant cloud services, setup and management of telehealth solutions, and security penetration testing for medical equipment.

ABOUT KEYPOINT INTELLIGENCE

For almost 60 years, clients in the digital imaging industry have relied on Keypoint Intelligence for independent hands-on testing, lab data, and extensive market research to drive their product and sales success. Keypoint Intelligence has been recognized as the industry’s most trusted resource for unbiased information, analysis, and awards due to decades of analyst experience. Customers have harnessed this mission-critical knowledge for strategic decision-making, daily sales enablement, and operational excellence—improving business goals and increasing bottom lines. With a central focus on clients, Keypoint Intelligence continues to evolve as the industry changes by expanding offerings and updating methods, while intimately understanding and serving manufacturers’, channels’, and their customers’ transformation in the digital printing and imaging sector.

ABOUT BUYERS LAB PACESETTER AWARDS

Based on exhaustive questionnaires, in-depth interviews, and a proprietary rating scale, Buyers Lab PaceSetter awards recognize document imaging OEMs that have shown market leadership in a variety of categories, including with technologies, services, and key vertical markets.

SOCIAL MEDIA

Connect with Keypoint Intelligence on LinkedIn

Follow Keypoint Intelligence on Twitter

CONTACT

Deanna Flanick

+1 973-797-2100

deanna.flanick@keypointintelligence.com

Share article on social media or email:



Sleep Quality Survey Uncovers Alarming Mental Health Concerns Due To Isolation & Stress


Puffy, has just released findings from a national sleep quality survey that reveals 61% of people are sleeping worse,

America’s Sleep Crisis: Sleep Quality Survey Results

There is no doubt that America is experiencing a sleep crisis that may have unprecedented consequences as more and more people transition to remote working

American-made bedroom company, Puffy, has just released findings from a national sleep quality survey that reveals 61% of people are sleeping worse, 82% of people are sleeping later, and 70% of people report poor sleep is impacting their mood. Amidst the already severe health crisis of the Covid pandemic, experts fear what many are calling a ‘sleep crisis’ is placing immunity and mental health at even greater risk.

Puffy surveyed over 4,400 adults from all 50 American states to get deeper insights into the sleep patterns, stress factors, and behavioral changes experienced by individuals during working from home orders amid the Covid pandemic.

As well as drastic declines in sleep duration across all demographics, sleep quality data indicates that people are experiencing significant sleep latency levels. Singles are the most at-risk group, with many respondents sighting loneliness and isolation as critical triggers for stress and low sleep quality.

Only 16% of singles reported sleep satisfaction; this number doubles among married respondents (32%). These insights indicate a strong correlation between sleeping alone, living alone, and poor mental health during Covid. Singles are the largest group in America who report staying awake due to thoughts racing through the mind. 74% of singles who participated in the Puffy Sleep Quality Survey report an inability to sleep due to late-night rumination and 71% of singles claim poor sleep negatively impacts mood.

The Puffy Sleep Quality Survey also finds that only 65% of singles prefer working from home, compared to a staggering 80% of married couples. A 2020 study by the Center for Integrative Psychiatry has found that couples who share a bed have increased and less disrupted rapid-eye-movement (REM) sleep compared to single sleepers.

The REM stage of sleep plays a vital role in helping individuals with a range of cognitive functions. Experts agree that improving REM sleep can have a significant impact on overall sleep quality and well-being.

“REM sleep helps to contribute to emotional regulation, learning, and memory. Deep sleep helps the brain to digest what was learned during the day as well as helping moods to be stable,” said Alaska Sleep Clinic expert at Jessica Hines.

Singles not only experience poorer sleep quality, they also report lower working from home productivity rates, with 46% of singles in the Sleep Quality Survey claiming they are less productive and 72% of married couples reporting they are more productive. Insights indicate that living in isolation can negatively impact energy, mood, sleep quality, and productivity when remote working.

The Sleep Quality Survey data released by Puffy confirms the comfort companies contention that sleep quality in America is plummeting at record rates and putting mental and physical well-being at risk. The uncertainty of Covid, along with the isolation of global lockdowns, has illuminated just how dire sleep satisfaction is in America and how closely sleep is linked to mental and physical health.

“While we are struck by the degree of sleep dissatisfaction and quality across all demographics in the US, we can’t say we are surprised. In stressful situations getting quality sleep can be a difficult task.

There is no doubt that America is experiencing a sleep crisis that may have unprecedented consequences as more and more people transition to remote working. Employers must step in to help employees, especially those living in isolation, create work-life balance where sleep is a priority,” said Puffy CEO Arthur Andreasyan.

To view comprehensive insights into Puffy’s Sleep Quality Survey click here: https://puffy.com/pages/sleep-survey

About Puffy

Puffy is a mattress and bedroom company currently operating in the United States and Canada. Puffy is deeply rooted in its commitment to develop complete bedroom solutions to help people sleep better and live better. Famous for inventing mattresses that feel like sleeping on a cloud, Puffy aims to deliver luxurious world-class comfort to transform sleep experiences worldwide.

Puffy sells all products direct-to-consumers online and was recently awarded Best Mattress of 2020. Puffy. For more information visit visit https://puffy.com.

Share article on social media or email:

Verge Genomics joins the Neurofilament Light Surveillance Project to Accelerate New Approaches to Diagnosing and Treating Frontotemporal Dementia


News Image

“Joining the NSP is part of Verge’s steadfast commitment to developing treatments for patients with complex neurodegenerative diseases,” said Jane Rhodes, Ph.D., M.B.A

Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-inhuman genomic platform with machine learning, announced today that it has joined the Neurofilament Light Surveillance Project (NSP), a consortium sponsored by the Bluefield Project to Cure FTD that brings together leading academic institutions, nonprofit foundations, and pharmaceutical and biotech companies to identify new approaches to diagnosing and treating frontotemporal dementia (FTD). The NSP study is an ancillary study of ALLFTD, a multisite observational research project aimed at preparing for clinical treatment trials in FTD. Coordinating research efforts to fund and share results through the NSP project will greatly accelerate the understanding of the mechanism of this disease and the development of new targets and approaches to treatment.

“Frontotemporal dementia is a rare but fatal adult-onset neurodegenerative disease where symptoms typically begin in middle-age and death usually occurs within 10 years after symptom onset. Joining the NSP is part of Verge’s steadfast commitment to developing treatments for patients with complex neurodegenerative diseases,” said Jane Rhodes, Ph.D., M.B.A. “Through this consortium, Verge will have access to data to aid biomarker development for monitoring and detecting disease progression, as well as providing data to advance clinical study design that will accelerate our ability to identify and develop potential new treatments for this devastating disease.”

The NSP (https://www.allftd.org/nsp) is a prospective, longitudinal, observational study that will collect blood samples from hundreds of participants over the course of three years. The study will help researchers to determine if plasma neurofilament light (NfL) may be used as a prognostic biomarker to select individuals with familial mutations at a high risk of converting to symptomatic disease within two years.

FTD encompasses a group of devastating neurodegenerative conditions that occur in people in their 50s or 60s and are characterized by dying neurons and the abnormal accumulation of proteins. Verge has active research and development programs aiming to find novel therapeutics for the treatment of neurodegenerative diseases, including FTD.

About Verge Genomics

Verge is focused on developing therapeutics for neurological diseases using human genomics to accelerate drug discovery. Verge has created a proprietary all-in-human platform, generating one of the field’s largest and most comprehensive databases of ALS, FTD and Parkinson’s Disease patient genomic data. The Company is led by experienced computational biologists and drug developers who are successfully advancing therapeutic programs in ALS and Parkinson’s disease toward the clinic. For additional information, please visit http://www.vergegenomics.com.

Share article on social media or email:

USOSM Moves into Oklahoma Market, Partners with Oral and Maxillofacial Associates LLC


USOSM President and CEO Richard Hall says the company is excited to announce its first Oklahoma partnership.

We’re honored to partner with such an outstanding practice, and we look forward to continuing to build strategic relationships in Oklahoma and throughout the nation.

U.S. Oral Surgery Management (USOSM) – a specialty management services company headquartered in Irving, Texas, that exclusively serves premier oral and maxillofacial surgeons – has entered into a new partnership with Oral and Maxillofacial Associates LLC (OMA) an oral and maxillofacial surgery (OMS) practice with six board-certified surgeons and four locations. The partnership is USOSM’s first in the state of Oklahoma.

“We’re excited to announce our first Oklahoma partnership, which is with OMA. This practice has been serving the Oklahoma community for more than 25 years. During that time, it has developed a well-earned reputation for outstanding patient care and clinical excellence, two characteristics that are also core to our values. We’re honored to partner with such an outstanding practice, and we look forward to continuing to build strategic relationships in Oklahoma and throughout the nation,” said Richard Hall, USOSM president and CEO.

OMA treats patients in Oklahoma City, Edmond, Midwest City and Norman. The surgeons offer a wide variety of OMS procedures to address both common and rare OMS needs, from wisdom teeth removal to teeth implants, sleep apnea correction and more.

“Our practice and USOSM have similar philosophies and values. We are both dedicated to putting patients first and to achieving the highest levels of clinical excellence in oral surgery. We both strive to advance and improve the quality of care for the people we serve; and together, we will make an even bigger difference in the health and lives of our patients. We look forward to this partnership, to working together and continuing to improve on the high-quality clinical care that OMA has been providing to our communities for over 25 years,” said Dr. Vincent E. Montgomery, a surgeon with OMA.

Headquartered in Irving, Texas, USOSM has partner practices spanning seven states: Texas, Colorado, Georgia, Tennessee, Minnesota, Alabama and Oklahoma. USOSM collaborates with premier oral and maxillofacial surgeons to offer a partnership solution for continued and accelerated practice success. USOSM provides operational, marketing and administrative support services, reinvests resources, and applies best practices to improve clinical and financial performance and produce steadier, more profitable growth for all.

Share article on social media or email:

Important Considerations for Outsourcing Biomarker Assays, Upcoming Webinar Hosted by Xtalks


In this webinar, the speakers will explain why biomarker assay outsourcing is different and will describe good practices and how a pharmaceutical company and a CRO can efficiently collaborate in this process.

A lot has already been written about the difference between biomarker assays and PK assays. However, in our daily work in a CRO setting, we still find that many potential sponsors are struggling with the challenges specific to biomarker outsourcing. It is not easy to clearly define a biomarker’s Context of Use (CoU) in a study or to get all the stakeholders involved in understanding the biology and use of the study data. It requires mutual understanding and close collaborations.

In this webinar, the speakers will explain why biomarker assay outsourcing is different and will describe good practices and how a pharmaceutical company and a CRO can efficiently collaborate in this process. PRA realizes that biomarker assays require special attention in order to provide reliable and useful data.

Join Radboud van Trigt, PhD, Director of Bioanalytical Science – Biomarkers, PRA Health Sciences and Amanda Hays, Ph.D., Director of Bioanalytical Science, PRA Health Sciences in a live webinar on Friday, November 13, 2020 at 10am EST (3pm GMT/UK) to gain insights from PRA about biomarker assay outsourcing.

For more information or to register for this event, visit Important Considerations for Outsourcing Biomarker Assays.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Why Conventional Wisdom Doesn’t Work, Upcoming Webinar Hosted by Xtalks


Powerful go-to-market and reimbursement strategies are two critical elements required to deliver great medtech products to the marketplace.

Relying on conventional wisdom leads to an estimated 72 percent of all new products and services failing to meet expectations.

On the other hand, successful medtech companies marry – from the very beginning – a technologist working on an as-yet unproven technology with a marketing person who is testing hypotheses about unmet market needs. It is a marriage that lasts until either the product is successfully launched or the technology is dropped.

Powerful go-to-market and reimbursement strategies are two critical elements required to deliver great medtech products to the marketplace.

Go-to-market strategy: Go-to-market (GTM) plans and performance directly impact every value creation moment throughout a company’s existence. That means GTM issues need to be top-of-mind every hour of every day. GTM is also difficult because success requires companies to simultaneously address product-centric challenges, organization-centric challenges, and marketplace-centric challenges. Tackling these three complex challenges requires the development of product-market fit, organizational fit, and business-model fit solutions, respectively.

Reimbursement strategy: Given the current healthcare environment, it is critical to articulate product value not only to clinicians but also other key stakeholders, such as payers. Reimbursement and revenue are inextricably linked; defining the clinical and economic value that a new technology has to its diverse stakeholders is essential to adoption, payer coverage and payment and ultimately revenue. Successful companies integrate their market access and reimbursement planning into the earliest phases of product development.

Join Mark Girardi, Senior Vice President, Boston Healthcare Associates and Donald B. Hawthorne, President, GTM Hawthorne in a live webinar on Thursday, November 12, 2020 at 1pm EST to learn how not to be conventional by exploring the key elements of successful go-to-market and reimbursement strategies that deliver great product and company value.

For more information, or to register for this event, visit Creating Great MedTech Products: Why Conventional Wisdom Doesn’t Work.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Applications of the immunoSEQ Assay Across the Clinical Development Pipeline, Upcoming Webinar Hosted by Xtalks


This webinar will use real-world data to demonstrate how immunosequencing can be leveraged at various points in the drug development and clinical trial process to improve the development of new therapies.

Immunosequencing, the science of profiling T- and B-cell receptors, has broad utility across the clinical development spectrum. Adaptive Biotechnologies’ quantitative immunoSEQ Technology has the ability to answer early, preclinical questions such as those around drug candidate selection, dosing and effective drug combinations. As a therapeutic pipeline matures to the clinical trial stage, the immunoSEQ Assay can also help confirm drug safety and efficacy, establish biomarker endpoints, optimize patient selection, predict response to therapy and monitor for adverse events.

This webinar will use real-world data to demonstrate how immunosequencing can be leveraged at various points in the drug development and clinical trial process to improve the development of new therapies.

Join Patrick Raber, PhD, Senior Manager of Research and Business Development, Adaptive Biotechnologies for the live webinar on Friday, November 13, 2020 at 10am PST (1pm EST).

For more information or to register for this event, visit From Bench to Biomarker: Applications of the immunoSEQ Assay Across the Clinical Development Pipeline.

The immunoSEQ Assay is For Research Use Only. Not for use in diagnostic procedures.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Susan G. Komen Chicago Commits $787,500 in 2020 to Decrease Breast Cancer Mortality Gap, Increase Access to Care for Communities of Greatest Need


Susan G. Komen Chicago

Komen Chicago’s ability to commit this funding, while in the midst of a pandemic, is monumental for our community.

In recognition of October’s Breast Cancer Awareness Month, Susan G. Komen Chicago is proud to announce a substantial commitment to initiating change in healthcare access for all Chicagoland women. In 2020 alone, the organization has committed $787,500 to advancing health equity for all and demolishing the racial disparities gap — a 68 percent increase in funding year over year.

“Although we’ve seen the breast cancer mortality rate decline in recent years, these benefits have been disproportionate and there is still evidence of a mortality gap between black and white patients nationally, with African American women 42 percent more likely to die from the disease,” said Dr. Tiosha Bailey, executive director of Komen Chicago. Also, in Chicago, African American women are 40 percent more likely to die from breast cancer than white women; for African American women aged 40 and under, the disparity increases to 157 percent.

“It is imperative to offer genetic counseling and testing to this demographic, especially here in Chicago, which is why Komen Chicago’s ability to commit this funding, while in the midst of a pandemic, is monumental for our community,” added Bailey.

Komen Chicago’s investment into the local community will help transform direct services and healthcare systems. Of the total investment:


  • $400,000 is committed to Chicago Health Equity Initiative (CHEI), a cohort of Chicago-area medical leaders who support healthcare systems’ transformation. In leading this cohort’s formation, Komen Chicago is evolving from exclusively funding breast health services to working collaboratively with a broad spectrum of partners to implement measurable and sustainable solutions that improve care and decrease costs. This is the first funding investment of its kind for Komen Chicago and the largest community investment made in the affiliate’s history.
  • $350,000 is funding local community grant programming that provides direct patient services for navigation, screening/diagnostic, and survivorship support programs in Komen Chicago’s five-county service area, including a strategic investment in McHenry County to help target the late stage breast cancer diagnosis rate identified in this area.
  • $37,5000 supports the Komen Chicago Treatment Assistance Program that provides patients who are in treatment with financial and psychosocial assistance programs to help reduce barriers and increase survival rates.


Komen Chicago has convened the following partners for CHEI: three Federally Qualified Health Centers (Access Community Health Network, Erie Family Health Centers and Friend Family Health Center), six major health systems in Cook County (Cook County Health and Hospital System, University of Chicago Medicine, University of Illinois Cancer Center, Rush University Medical Center, Northwestern University Cancer Center and Sinai Health System), the Illinois Medical District, American Cancer Society and Chicago Department of Public Health. The CHEI implementation plan is currently being developed, with services scheduled to begin in 2021.

The University of Illinois (UI) Cancer Center at UI Health has been designated as the Komen Chicago Lead in the CHEI consortium. The UI Cancer Center’s community-facing mission and commitment to promote health equity and eradicate cancer disparities in Chicago communities and beyond make it an ideal lead partner.

“Not only will CHEI work tirelessly to decrease health disparities across our city, but we will be firm advocates for education and access for all by raising awareness of these key initiatives to our community members and neighbors,” said CHEI director, Dr. John H. Stewart from UI Cancer Center.

“We are so proud to bring together this revolutionary consortium of Chicago’s top medical leaders to create actionable change within the systems of our current healthcare structure,” said Dr. Suzet McKinney, president of Komen Chicago’s Board of Directors and CHEI partner representing the Illinois Medical District. “We have three key goals at hand — decrease breast mortality disparities across Chicagoland, reduce the detection-to-diagnosis interval, and increase the number of high-risk women under age 40 who receive genetic screening.”

“Through CHEI, we will work to implement genetic counseling and testing in the primary care setting to increase early detection of breast cancer,” said Dr. Olufunmilayo I. Olopade, Director of the Center for Clinical Cancer Genetics & Global Health and Medical Oncologist at the University of Chicago Medical Center. “The sooner we can detect signs of breast cancer, the sooner we can begin treatment and lower breast cancer mortality across the board.”

Since 1997, Komen Chicago has invested over $18.5 million in local community grants and $6 million in breakthrough research. The organization has reaffirmed its continued mission of investing 100 percent of net proceeds back into local community grantmaking and research initiatives for more than two decades. In the coming months, Susan G. Komen’s national headquarters is moving forward with plans to consolidate all Komen affiliates into One Komen.

“As a result of the current climate, changes must occur to maintain Komen’s national commitment to preventing and curing breast cancer. Komen Chicago is working with the national team to ensure a strong local impact remains for Chicago-area women,” added Bailey.

For more information on Komen Chicago, its programs and the Chicago Health Equity Initiative, please visit http://www.komenchicago.org.

About Komen Chicago

Susan G. Komen’s promise is to save lives by meeting the most critical needs in our communities and investing in breakthrough research to prevent and cure breast cancer. Komen Chicago donates 100 percent of net funds raised to community grants and global research. Komen Chicago’s priorities include making sure everyone has access to quality healthcare options, fighting to ensure fewer people die from metastatic breast cancer and shining a light on the importance of early detection. For more information visit komenchicago.org.

Share article on social media or email:

Black Women Owned Slumber Bliss Seat Covers Launches Line of Antimicrobial Seat Covers and Other Travel Safety Products During this Time of COVID-19


Slumber Bliss in action

Slumber Bliss in action

Since retiring from playing in the NFL I took on a Scout Consultant role with the Philadelphia Eagles and with all the traveling I do my Slumber Bliss seat cover has been one of my favorite traveling necessities. I never leave home without it

One never knows what kind of germs, viruses and bacteria are lurking on seat surfaces of buses, trains and airplanes, especially during this time of COVID-19. The easy safe solution? Patent Pending Slumber Bliss re-usable antimicrobial seat covers! They are the simplest way to protect yourself and your family during travel from germs, bacteria, allergens, and pathogens that may be on contaminated seats that can cause illnesses or bacterial infections. Proudly made in the USA and accepted by all airlines and travel providers around the world, these universal seat covers are launching to high demand as one of the newest traveling necessities preferred by safe and savvy travelers.

Founded by Nichale Denby and Nichole Denby-Jackson, the dynamic sisters found a way to help travelers in the midst of one of the most uncertain and challenging times that the human race has ever faced. During the early days of the pandemic, the sisters were informed that a family friend tested positive for COVID-19. With the fear of possibly contacting the deadly virus from sitting and touching unsanitary seats while flying, the sisters came up with a superb idea to create reusable antimicrobial airplane seat covers. Nichale and Nichole had a seamstress develop a few samples out of soft, high quality antimicrobial fabric to sell to their close friends and family members.

One of the main goals of launching a company around their popular seat covers was to gather funds to make an impact by giving back to essential workers. The sisters used some of the seat cover sales proceeds to deliver food and much needed medical supplies, including PPE, to local hospitals in Los Angeles and surrounding areas. The duo also made errands and grocery store runs for individuals at high risk for COVID-19 in hopes to mitigate their risk of becoming infected. After receiving so many compliments and praise from fellow airline passengers, friends, and family on their safety seat covers’ design, they decided to take it to the next level and mass produce the seat covers for the general public across the globe.

Moving forward, the Denby Sisters will continue their philanthropic efforts and donate a portion of all proceeds to a charitable organization selected by the public through submissions to their website each quarter.

All Patent Pending Slumber Bliss seat covers come with a clear waterproof seat cover tote. The Slumber Bliss product line also includes disposable seat covers, sanitary travel kit, plush blanket attachment, and copper infused compression socks. All seat covers can also be used on most buses, trains, automobiles, and movie theater seats.

Nichale Denby, MBA, is a HBCU graduate that is balancing her respectable career as both a tech executive and entrepreneur. Currently flourishing in a successful career in tech and entrepreneurship like her sister, Nichole Denby-Jackson was also a world class athlete – she ran the 100-meter hurdles for the USA team in the 2007 World Championships, and was an USA Olympic Team alternate in 2008. To date, there have been some high-flying sports figures who were early adopters and are now ambassadors of Slumber Bliss seat covers. These include Bradie James, former NFL Linebacker for the Dallas Cowboys, Darren Sproles, former Pro Bowl and Super Bowl Champion Running Back for the Philadelphia Eagles, and Sanya Richards-Ross, an Olympic Gold Medalist and American Record Holder in the 400 meters.

Sproles notes, “Since retiring from playing in the NFL I took on a Scout Consultant role with the Philadelphia Eagles and with all the traveling I do my Slumber Bliss seat cover has been one of my favorite traveling necessities. I never leave home without it!”

Share article on social media or email: